Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma

Pascal Syren, Roland Andersson, Monika Bauden, Daniel Ansari

Research output: Contribution to journalReview articlepeer-review


Pancreatic ductal adenocarcinoma (PDAC) prognosis remains very poor and has only marginally improved during the last decades. Epigenetic alterations have been the focus of many recent studies and offer valuable options for PDAC detection, prognosis and treatment. DNA methylation, histone modifications and microRNA (miR) level changes can be used as biomarkers. These alterations occur early in carcinogenesis and may be specific for PDAC. Additionally, epigenetic alterations can be analyzed from cell-free DNA, free-circulating nucleosomes or shed tumor cells in blood. High-throughput methods are available for miR and DNA methylation level detection. In particular, multiple promising miR level changes have been discovered. No single epigenetic biomarker that offers a sufficient specificity has been discovered yet, but patterns containing multiple independent biomarkers exist.

Original languageEnglish
Pages (from-to)668-673
JournalScandinavian Journal of Gastroenterology
Issue number6-7
Publication statusPublished - 2017 Jul 3

Subject classification (UKÄ)

  • Cancer and Oncology
  • Gastroenterology and Hepatology

Free keywords

  • biomarkers
  • diagnosis
  • DNA methylation
  • epigenetics
  • histone modifications
  • microRNA
  • Pancreatic cancer


Dive into the research topics of 'Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this